Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atreca, Inc.BCEL · Entity 91940 | Director | June 13, 2023 | June 15, 2023 |
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Director | January 07, 2026 | January 09, 2026 |
| Clovis Oncology, Inc.CLVS · Entity 122635 | See Remarks | November 01, 2022 | November 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atreca, Inc.
Report date June 13, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2023-06-12 | Direct | 12,000 |
Reported balance
After 2023-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 12,000 · Balance 12,000 F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.
CERO THERAPEUTICS HOLDINGS, INC.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2036-01-06 | Direct | 690,900 |
Reported balance
After 2026-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 690,900 · Balance 690,900 |
Clovis Oncology, Inc.
Report date November 01, 2022 · Filed November 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,327 |
Reported balance
After 2022-11-01 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-11-01 · Exercise / conversion · Acquired 3,749 · Balance 113,327 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 111,419 |
Reported balance
After 2022-11-02 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-11-02 · Sale · Disposed 1,908 · Balance 111,419 F2: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 116,044 |
Reported balance
After 2022-11-01 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2022-11-01 · Exercise / conversion · Acquired 4,625 · Balance 116,044 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 113,691 |
Reported balance
After 2022-11-02 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2022-11-02 · Sale · Disposed 2,353 · Balance 113,691 F2: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,750 |
Reported balance
After 2022-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-01 · Exercise / conversion · Disposed 3,749 · Balance 3,750 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,125 |
Reported balance
After 2022-11-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-01 · Exercise / conversion · Disposed 4,625 · Balance 23,125 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F5: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F5: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2026 Filed Jan 9, 2026 16:30 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 690,900 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001213900-26-002949 · ownership.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 690,900 Underlying: Common Stock · 690,900 shares Expires 2036-01-06 Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 17:06 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 9,326 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001213900-25-050123 · ownership.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,326 Underlying: Common Stock · 9,326 shares Expires 2035-05-29 F1 · shares: Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions. F1 · derivative.exercise_date: Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:16 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 17,923 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001213900-25-021190 · ownership.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,923 Underlying: Common Stock · 17,923 shares Expires 2035-03-03 F1 · shares: Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions. F1 · derivative.exercise_date: Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 18:06 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 127,500 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001213900-25-017524 · ownership.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 127,500 shares Expires 2034-09-30 F1 · derivative.exercise_date: On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 127,500 shares. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:12 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 127,500 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001213900-24-105729 · ownership.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,500 Underlying: Common Stock · 127,500 shares Expires 2034-09-30 F1 · derivative.exercise_date: On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On December 2, 2024, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 127,500 shares. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 21:29 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001213900-24-026824 · ownership.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2034-03-24 F1 · derivative.exercise_date: The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 18:10 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-23-037521 · doc4.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Class A Common Stock · 12,000 shares Expires 2023-06-12 F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,353 | $0.98 | $2,312.76 |
DisclosureSEC source: 0000899243-22-034890 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,691 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 1,908 | $0.98 | $1,875.37 |
DisclosureSEC source: 0000899243-22-034890 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,419 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 4,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-034890 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,125 Underlying: Common Stock · 4,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F5 · derivative.exercise_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F5 · derivative.expiration_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,749 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-034890 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · derivative.exercise_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 4,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-034890 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 3,749 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-034890 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,545 | $1.20 | $3,054.00 |
DisclosureSEC source: 0000899243-22-030421 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,578 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 5,063 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030421 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,625 Underlying: Common Stock · 5,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F3 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date F3 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 5,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-030421 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,391 | $1.46 | $3,493.01 |
DisclosureSEC source: 0000899243-22-027577 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,060 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $ 1.4600 to $1.4947. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 1,939 | $1.46 | $2,832.69 |
DisclosureSEC source: 0000899243-22-027577 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,826 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $ 1.4600 to $1.4947. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 4,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-027577 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,750 Underlying: Common Stock · 4,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F5 · derivative.exercise_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F5 · derivative.expiration_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,749 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-027577 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,499 Underlying: Common Stock · 3,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · derivative.exercise_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 4,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-027577 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 3,749 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-027577 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 18:42 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-22-036101 · doc4.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Class A Common Stock · 12,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,650 | $0.64 | $1,702.63 |
DisclosureSEC source: 0000899243-22-020946 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,016 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $0.642368 to $0.645500. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 5,062 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020946 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,688 Underlying: Common Stock · 5,062 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date F4 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 5,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020946 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| May 02, 2022 Filed May 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,348 | $1.97 | $4,625.09 |
DisclosureSEC source: 0000899243-22-016295 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,604 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $1.9518 to $1.9700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 02, 2022 Filed May 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 1,904 | $1.97 | $3,750.50 |
DisclosureSEC source: 0000899243-22-016295 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,327 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $1.9518 to $1.9700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2022 Filed May 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 4,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016295 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,375 Underlying: Common Stock · 4,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F5 · derivative.exercise_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F5 · derivative.expiration_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| May 01, 2022 Filed May 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,749 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016295 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,248 Underlying: Common Stock · 3,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · derivative.exercise_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| May 01, 2022 Filed May 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 4,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-016295 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| May 01, 2022 Filed May 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 3,749 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-016295 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 10,585 | $1.87 | $19,751.61 |
DisclosureSEC source: 0000899243-22-009062 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,482 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $1.862 to $1.866. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 360 | $1.87 | $671.76 |
DisclosureSEC source: 0000899243-22-009062 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,817 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $1.862 to $1.866. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 688 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009062 · doc4.xml · derivative · entry 7 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F6 · derivative.exercise_date: On March 1, 2018 , the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F6 · derivative.expiration_date: On March 1, 2018 , the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 20,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009062 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,750 Underlying: Common Stock · 20,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F5 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date F5 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantRestricted Stock Units · Derivative | 81,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009062 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units shall vest as to 25% of the units on March 1, 2023, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: The Restricted Stock Units shall vest as to 25% of the units on March 1, 2023, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 20,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-009062 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 688 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-009062 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 16:17 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,493 | $1.94 | $4,835.67 |
DisclosureSEC source: 0000899243-22-004583 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,489 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 16:17 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,021 | $1.94 | $3,919.93 |
DisclosureSEC source: 0000899243-22-004583 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,357 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:17 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 4,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-004583 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 4,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F5 · derivative.exercise_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F5 · derivative.expiration_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:17 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-004583 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,997 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · derivative.exercise_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:17 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 4,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-004583 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:17 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-004583 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 16:16 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 346 | $3.00 | $1,038.00 |
DisclosureSEC source: 0000899243-21-046772 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,628 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: On March 1, 2018, the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 16:16 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 687 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-046772 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688 Underlying: Common Stock · 687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F3 · date: On March 1, 2018, the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.exercise_date: On March 1, 2018, the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.expiration_date: On March 1, 2018, the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 16:16 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-046772 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 16:18 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,325 | $4.55 | $10,578.75 |
DisclosureSEC source: 0000899243-21-042707 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,287 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 16:18 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 1,884 | $4.55 | $8,572.20 |
DisclosureSEC source: 0000899243-21-042707 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,987 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.